Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Edgewise Therapeutics (EWTX)
NASDAQ:EWTX
RESEARCH TOOLSreports
EWTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.90 - $38.12
Previous CloseN/A
Volume107.81K
Average Volume (3M)959.29K
Market Cap
$2.47B
Enterprise Value$2.02B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.02
Next Earnings
Feb 20, 2025EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.49
Shares Outstanding94,688,515
10 Day Avg. Volume980,813
30 Day Avg. Volume959,286
Standard Deviation0.22
R-Squared0.00206
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-22.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.16K
Enterprise Value/Ebitda-13.89
Forecast
1Y Price Target
$46.40Price Target Upside73.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Edgewise Therapeutics News
PremiumCompany Announcements
Edgewise Therapeutics Promotes Derakhshan to COO Role
---
Bulls Say, Bears Say
Bulls Say
Clinical ResultsThe topline phase 2 CANYON results for sevasemten in BMD exceeded expectations, showing significant improvements in several key measures compared to placebo.
Market PotentialThe stock traded up ~25%, reflecting the Street's appreciation for the data and a path to accelerated approval in BMD.
Regulatory ProgressEWTX plans to complete recruitment in the GRAND CANYON pivotal placebo-controlled cohort, which aligns with their goal to approach the FDA for potential accelerated approval.
Bears Say
Data ImbalancesThere are significant NSAA baseline imbalances in the sevasemten ph2 BMD data, making it hard to have real conviction that these data support accelerated approval.
Differentiation ChallengeThe window to clearly differentiate from aficamten is narrow, and the path to doing so is tricky with high regulatory bar.
Stock PerformanceThe stock has gradually traded down since EWTX's Becker muscular dystrophy readout.
---
Ownership Overview
31.71% Insiders
11.78% Mutual Funds
<0.01% Other Institutional Investors
47.05% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EWTX FAQ
What was Edgewise Therapeutics’s price range in the past 12 months?
Edgewise Therapeutics lowest stock price was $14.90 and its highest was $38.12 in the past 12 months.
What is Edgewise Therapeutics’s market cap?
Edgewise Therapeutics’s market cap is $2.47B.
When is Edgewise Therapeutics’s upcoming earnings report date?
Edgewise Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is yesterday.
How were Edgewise Therapeutics’s earnings last quarter?
Edgewise Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.372 by $0.012.
Is Edgewise Therapeutics overvalued?
According to Wall Street analysts Edgewise Therapeutics’s price is currently Undervalued.
Does Edgewise Therapeutics pay dividends?
Edgewise Therapeutics does not currently pay dividends.
What is Edgewise Therapeutics’s EPS estimate?
Edgewise Therapeutics’s EPS estimate is -0.42.
How many shares outstanding does Edgewise Therapeutics have?
Edgewise Therapeutics has 94,688,515 shares outstanding.
What happened to Edgewise Therapeutics’s price movement after its last earnings report?
Edgewise Therapeutics reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.372. Following the earnings report the stock price went down -3.25%.
Which hedge fund is a major shareholder of Edgewise Therapeutics?
Currently, no hedge funds are holding shares in EWTX
---
Edgewise Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$46.40 (73.98% Upside)
$46.40 (73.98% Upside)
Blogger Sentiment
Bullish
EWTX Sentiment 75%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $3.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.54%
12-Months-Change
Fundamentals
Return on Equity
-31.90%
Trailing 12-Months
Asset Growth
64.21%
Trailing 12-Months
Company Description
Edgewise Therapeutics
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
---
EWTX Stock 12 Month Forecast
Average Price Target
$46.40
▲(73.98% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Sarepta Therapeutics
―
PTC Therapeutics
―
Ultragenyx Pharmaceutical
―
Avidity Biosciences
―
Best Analysts Covering EWTX
1 Year
1 Year Success Rate
16/25 ratings generated profit
1 Year Average Return
+72.14%
reiterated a buy rating last month
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 64.00% of your transactions generating a profit, with an average return of +72.14% per trade.
---